[go: up one dir, main page]

WO2012061060A1 - Utilisation de tériflunomide pour le traitement d'atrophie cérébrale - Google Patents

Utilisation de tériflunomide pour le traitement d'atrophie cérébrale Download PDF

Info

Publication number
WO2012061060A1
WO2012061060A1 PCT/US2011/057456 US2011057456W WO2012061060A1 WO 2012061060 A1 WO2012061060 A1 WO 2012061060A1 US 2011057456 W US2011057456 W US 2011057456W WO 2012061060 A1 WO2012061060 A1 WO 2012061060A1
Authority
WO
WIPO (PCT)
Prior art keywords
teriflunomide
patient
brain
volume
reduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/057456
Other languages
English (en)
Inventor
Ross Rocklin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis US LLC
Original Assignee
Sanofi Aventis US LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis US LLC filed Critical Sanofi Aventis US LLC
Publication of WO2012061060A1 publication Critical patent/WO2012061060A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • This invention relates to use of teriflunomide for slowing the reduction of the volume of white matter in the brain, particularly in a patient having multiple sclerosis (MS).
  • MS multiple sclerosis
  • Teriflunomide is a novel oral disease-modifying therapy (DMT) in development for the treatment of relapsing-remitting multiple sclerosis (RMS).
  • DMT oral disease-modifying therapy
  • RMS multiple sclerosis
  • Teriflunomide blocks de novo pyrimidine synthesis, which inhibits the replication and function of activated (but not resting) lymphocytes.
  • This invention relates to a method for slowing the reduction of the volume of white matter in the brain, comprising administering to a patient in need thereof a
  • teriflunomide or a pharmaceutically acceptable salt thereof.
  • Figure I shows the change from baseline in volume of white matter over time of the three patient groups in the TEMSO study.
  • a compound that slows the reduction of the volume of grey matter in the brain means a compound that is already known for slowing the reduction of the volume of grey matter in the brain, such as fingolimod.
  • “Clinically proved effective” means that the results of clinical trial are statistically significant, i.e., the results of the clinical trial are not likely to be due to chance with an alpha level les than 0.05. "Patient” means humans.
  • “Pharmaceutically acceptable salt” refers to the relatively non-toxic, inorganic and organic acid addition salts, and base addition salts, of teriflunomide. "Pharmaceutically effective amount” means an amount of a compound/composition according to the present invention effective in producing the desired therapeutic effect.
  • Treating means to alleviate symptoms, eliminate the causation of the symptoms either on a temporary or permanent basis, or to slow the appearance of symptoms of the named disorder or condition.
  • One specific embodiment of the invention relates to a method for slowing the reduction of the volume of white matter in the brain, comprising administering to a patient having multiple sclerosis a pharmaceutically effective amount of teriflunomide or a pharmaceutically acceptable salt thereof.
  • Another specific embodiment of the invention relates to a method for slowing the reduction of the volume of white matter in the brain, comprising administering to a patient having multiple sclerosis a pharmaceutically effective amount of teriflunomide.
  • Another specific embodiment of the invention relates to a method for slowing the reduction of the volume of white matter in the brain, comprising administering to a patient having relapse-remitting form of multiple sclerosis a pharmaceutically effective amount of teriflunomide.
  • Another specific embodiment of the invention relates to a method for slowing the reduction of the volume of white matter in the brain, comprising administering to a patient having relapse-remitting multiple sclerosis about 7 mg or about 14 mg of teriflunomide daily.
  • Another specific embodiment of the invention relates to a method for slowing the reduction of the volume of white matter in the brain, comprising administering to a patient having relapse-remitting multiple sclerosis about 14 mg of teriflunomide daily, wherein the method is clinically proven effective.
  • Another specific embodiment of the invention relates to a method for treating brain atrophy, comprising administering to a patient having multiple sclerosis a
  • teriflunomide or a pharmaceutically acceptable salt thereof and a compound that slows the reduction of the volume of gray matter in the brain.
  • Another specific embodiment of the invention relates to teriflunomide for use in reducing the volume of white matter in brain in a patient having multiple sclerosis.
  • Another specific embodiment of the invention relates to teriflunomide for use in slowing the reduction of the volume of white matter in brain in a patient having relapse-remitting form of multiple sclerosis.
  • Another specific embodiment of the invention relates to teriflunomide for use in slowing the reduction of the volume of white matter in brain in a patient having relapse-remitting form of multiple sclerosis, wherein teriflunomide is administered to the patient about 7 mg or about 14 mg daily.
  • Another specific embodiment of the invention relates to teriflunomide for use in slowing the reduction of the volume of white matter in brain in a patient having relapse-remitting form of multiple sclerosis, wherein teriflunomide is administered to the patient about 14 mg daily, and wherein the use is clinically proved effective.
  • teriflunomide and a compound that slows the reduction of the volume of grey matter in the brain of a patient.
  • Another specific embodiment of the invention relates to a combination of teriflunomide and a compound that slows the reduction of the volume of grey matter in the brain of a patient for use in treating brain atrophy.
  • Example 1 is exemplary of the invention. They should in no way be construed, however, as limiting the broad scope of the invention.
  • Patients eligible for enrolment were aged 18-55 years, met McDonald's criteria for MS diagnosis, and exhibited a relapsing clinical course, with or without progression. They were required to have a score of no more than 5.5 on the Kurtzke Expanded Disability Status Scale (EDSS), a minimum of two clinical relapses in the previous 2 years or one relapse during the preceding year, but no relapses in the 60 days before randomization. During the 4 weeks prior to randomization, patients were required to be clinically stable and have signed both the informed consent form and informed consent for H IV testing .
  • EDSS Kurtzke Expanded Disability Status Scale
  • cladribine Prior or concomitant use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporine, methotrexate or mycophenolate
  • MRI Contraindication for MRI including presence of pacemaker, metallic implants in high-risk areas (e.g. artificial heart valves, aneurysm/vessel clips), presence of metallic material (e.g. shrapnel) in high-risk areas, known history of allergy to any contrast medium, or history of claustrophobia that would prevent completion of all protocol-scheduled MRI visits; hip implants were not contraindicated
  • high-risk areas e.g. artificial heart valves, aneurysm/vessel clips
  • metallic material e.g. shrapnel
  • HlV Human immunodeficiency virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne l'utilisation de tériflunomide pour ralentir la réduction du volume de la matière blanche dans le cerveau, en particulier chez un patient atteint de sclérose en plaques.
PCT/US2011/057456 2010-10-25 2011-10-24 Utilisation de tériflunomide pour le traitement d'atrophie cérébrale Ceased WO2012061060A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40629110P 2010-10-25 2010-10-25
US61/406,291 2010-10-25
US201161487998P 2011-05-19 2011-05-19
US61/487,998 2011-05-19

Publications (1)

Publication Number Publication Date
WO2012061060A1 true WO2012061060A1 (fr) 2012-05-10

Family

ID=44913414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/057456 Ceased WO2012061060A1 (fr) 2010-10-25 2011-10-24 Utilisation de tériflunomide pour le traitement d'atrophie cérébrale

Country Status (1)

Country Link
WO (1) WO2012061060A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021176070A1 (fr) * 2020-03-06 2021-09-10 Actelion Pharmaceuticals Ltd Procédés de ralentissement de la perte de volume cérébral
US11951097B2 (en) 2021-10-11 2024-04-09 Vanda Pharmaceuticals Inc. Methods of treating multiple sclerosis
US12357616B2 (en) 2021-10-11 2025-07-15 Vanda Pharmaceuticals Inc. Methods of treating multiple sclerosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679709A (en) 1985-09-27 1997-10-21 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases
US6794410B2 (en) 2001-04-05 2004-09-21 Aventis Pharmaceuticals Inc. Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679709A (en) 1985-09-27 1997-10-21 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases
US6794410B2 (en) 2001-04-05 2004-09-21 Aventis Pharmaceuticals Inc. Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERMEL ET AL.: "The measurement and clinical relevance of brain atrophy in multiple sclerosis", LANCET NEUROL, vol. 5, 2006, pages 158 - 70, XP024968905, DOI: doi:10.1016/S1474-4422(06)70349-0
LOSSEFF N A ET AL: "Progressive cerebral atrophy in multiple sclerosis: A serial MRI study", BRAIN, vol. 119, no. 6, 1996, pages 2009 - 2019, XP002665107, ISSN: 0006-8950 *
O'CONNOR P W ET AL: "A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 66, no. 6, 28 March 2006 (2006-03-28), pages 894 - 900, XP002556504, ISSN: 0028-3878, DOI: 10.1212/01.WNL.0000203121.04509.31 *
SIMON JH: "Brain atrophy in multiple sclerosis: what we know and would like to know", MULTIPLE SCLEROSIS, vol. 12, 2006, pages 679 - 687, XP009154478, DOI: doi:10.1177/1352458506070823
TEDESCHI G ET AL: "Brain atrophy and lesion load in a large population of patients with multiple sclerosis", NEUROLOGY, vol. 65, no. 2, July 2005 (2005-07-01), pages 280 - 285, XP002665108, ISSN: 0028-3878 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021176070A1 (fr) * 2020-03-06 2021-09-10 Actelion Pharmaceuticals Ltd Procédés de ralentissement de la perte de volume cérébral
US11951097B2 (en) 2021-10-11 2024-04-09 Vanda Pharmaceuticals Inc. Methods of treating multiple sclerosis
US12357616B2 (en) 2021-10-11 2025-07-15 Vanda Pharmaceuticals Inc. Methods of treating multiple sclerosis
US12419869B2 (en) 2021-10-11 2025-09-23 Vanda Pharmaceuticals Inc. Methods of treating multiple sclerosis

Similar Documents

Publication Publication Date Title
JP2010070566A (ja) ウイルス性肝炎の処置
JP2009522371A5 (fr)
Chang et al. Injectable RANKL sustained release formulations to accelerate orthodontic tooth movement
US12343371B2 (en) Method for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using a sustained release depot formulation comprising glatiramer acetate
KR20150040338A (ko) 다발경화증 치료용 조합 요법
RU2012133528A (ru) Способ лечения аутоиммунного демиелинизирующего заболевания центральной нервной системы (варианты)
ES2952044T3 (es) Sistemas de depósito que comprenden acetato de glatiramer
Masalskas et al. Local delivery of strontium ranelate promotes regeneration of critical size bone defects filled with collagen sponge
WO2012061060A1 (fr) Utilisation de tériflunomide pour le traitement d'atrophie cérébrale
US20080279819A1 (en) Combinations Therapy for Treatment of Demyelinating Conditions
Wang et al. Adhesive and injectable hydrogel microspheres for NRF2-mediated periodontal bone regeneration
JP2007524616A (ja) Ｈｉｖを処置するための組成物および方法
EP2600861A1 (fr) Utilisation de tériflunomide dans le traitement de la sclérose en plaques
WO2012162339A1 (fr) Utilisation du tériflunomide pour réduire l'occurrence des récidives nécessitant des ressources de soins de santé
Tullman et al. Combination therapy in multiple sclerosis
US20130197080A1 (en) Use of teriflunomide for treating multiple sclerosis
WO2012116128A1 (fr) Utilisation de tériflunomide pour le traitement de trouble cognitif
Garassino et al. Bevacizumab for non-small-cell lung cancer
Colombani et al. Harnessing the Potential of Biomaterials for COVID-19 Therapeutic Strategies
WO2024104290A1 (fr) Méthode de traitement de la sclérose en plaques
JP5485704B2 (ja) 骨吸収と骨形成の不均衡を是正するための方法ならびにキット及び組成物
US20130102662A1 (en) Use of inducible nitric oxide synthase inhibitors and nitric oxide scavengers to inhibit post-traumatic immunodepression
WO2015166071A1 (fr) Thérapie combinée pour le traitement d'une infection par le hvc
JPWO2021003279A5 (fr)
Sullivan Happening Now.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11779915

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11779915

Country of ref document: EP

Kind code of ref document: A1